|
[1]
|
B. A. Rogers, H. E. Sidjabat and D. L. Paterson, “Escherichia coli O25b-ST131: A Pandemic, Multiresistant, Community-Associated Strain,” Journal of Antimicrobial Chemotherapy, Vol. 66, No. 1, 2011, pp. 1-14.
doi:10.1093/jac/dkq415
|
|
[2]
|
J. D. D. Pitout and K. P. Laupland, “Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: An Emerging Public-Health Concern,” Lancet Infectious Diseases, Vol. 8, No. 1, 2008, pp. 159-166.
doi:10.1016/S1473-3099(08)70041-0
|
|
[3]
|
J. D. D. Pitout, “Entraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance,” Frontiers in Microbiology, Vol. 3, No. 1, 2012, pp. 1-7. doi:10.3389/fmicb.2012.00009
|
|
[4]
|
C. Urban, N. Mariano, P. A. Bradford, M. Tuckman, S. Segal-Maurer, W. Wehbeh, L. Grenner, R. Colon-Urban, B. Johnston, J. R. Johnson and J. J. Rahal, “Identification of CTX-M β-Lactamases in Escherichia coli From Hospitalized Patients and Residents of Long-Term Care Facilities,” Diagnostic Microbiology and Infectious Disease, Vol. 66, No. 4, 2010, pp. 402-406.
doi:10.1016/j.diagmicrobio.2009.11.012
|
|
[5]
|
H. Tiruvury, N. Mariano, L. Grenner, R. Colon-Urban, M. Erritouni, W. Wehbeh, S. Segal-Maurer, J. J. Rahal, B. Johnston, J. R. Johnson and C. Urban, “Identification of CTX-M β-Lactamases in Escherichia coli From the Community,” Diagnostic Microbiology and Infectious Disease, Vol. 72, No. 3, 2012, pp. 248-252.
doi:10.1016/j.diagmicrobio.2011.11.008
|
|
[6]
|
K. L. Woods, J. R. Johnson, S. Padkowsky, N. Mariano, R. Colon-Urban, M. Hassanein, W. Wehbeh, B. D. Johnston, C. Clabots, S. Zahid and C. Urban, “Community Associated Escherichia coli Harboring CTX-M-15 β-Lactamases Isolated From Urine Cultures in Pediatric Patients,” Antimicrobial Agents and Chemotherapy, Vol. 56, No. 4, 2012, pp. 2209-2210. doi:10.1128/AAC.00003-12
|
|
[7]
|
H. E. Sidjabat, D. L. Paterson, J. M. Adams-Haduch, L. Ewan, A. W. Pasculle, C. A. Muto, G. B. Tian and Y. Doi, “Molecular Epidemiology of CTX-M-producing Escherichia coli at a Tertiary Medical Center in Western Pennsylvania,” Antimicrobial Agents and Chemotherapy, Vol. 53, No. 11, 2009, pp. 4733-4739.
doi:10.1128/AAC.00533-09
|
|
[8]
|
K. B. Laupland, D. B. Gregson, D. L. Church, T. Ross and J. D. D. Pitout, “Incidence, Risk Factors and Outcomes of Escherichia coli Bloodsteam Infections in a Large Canadian Region,” Clinical Microbiology and Infection Vol. 14, No. 11, 2008, pp. 1041-1047.
doi:10.1111/j.1469-0691.2008.02089.x
|
|
[9]
|
J. Rodriguez-Bano, E. Picon, J. R. Hernandez, M. Ruiz, C. Pena, M. Almela, B. Almirante, F. Grill, J. Golomina, A. Oliver, J. P. Horcajada, G. Navarro, A. Coloma and A. Pascaul, “Community-Onset Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: Risk Factors and Prognosis,” Clinical Infectious Diseases, Vol. 50, No. 1, 2010, pp. 40-48. doi:10.1086/649537
|
|
[10]
|
S. H. Park, S-M Choi, D-G. Lee, J. Kim, J-H. Choi, S-H Kim, J.-C. Kwon and J.-H. Yoo, “Emergence of Extended-Spectrum β-Lactamase-Producing Escherichia coli as a Cause of Community-Onset Bacteremia in South Korea: Risk Factors and Clinical Outcomes,” Microbial Drug Resistance, Vol. 17, No. 4, 2011, pp. 537-544.
doi:10.1089/mdr.2011.0072
|
|
[11]
|
D. Marchaim, T. Gottesman, O. Schwartz, M. Korem, Y. Maor, G. Rahav, R. Karplus, T. Lazarovitch, E. Braun, H. Sprecher, T. Lachish, Y. Wiener-Well, D. Alon, M. Chowers, P. Ciobotaro, R. Bardenstein, A. Paz, I. Potas-man, M. Giladi, V. Schechner, M. J. Schwaber, S. Klarfeld-Lidji and Y. Carmeli, “National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases,” Antimicrobial Agents and Chemotherapy, Vol. 54, No. 12, 2010, pp. 5099-5104.
doi:10.1128/AAC.00565-10
|
|
[12]
|
V. P. Chaubey, J. D. D. Pitout, B. Dalton, T. Ross, D. L. Church, D. B. Gregson and K. B. Laupland, “Clinical Outcome of Empiric Antimicrobial Therapy of Bacteremia Due to Extended-Spectrum Beta-Lactamase Producing Escherichia coli and Klebsiella pneumoniae,” BMC Research Notes, Vol. 3, 2010, pp. 116-122.
doi:10.1186/1756-0500-3-116
|
|
[13]
|
L. Chandramohan and P. A. Revell, “Prevalence and Molecular Characterization of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in a Pediatric Patient Population,” Antimicrobial Agents and Chemotherapy, Vol. 56, No. 9, 2012, pp. 4765-4770.
doi:10.1128/AAC.00666-12
|
|
[14]
|
S. Boyer-Mariotte, P. Duboc, S. Bonacorsi, J. F. Lemeland, E. Bingen and D. Pinquier, “CTX-M-15-Producing Escherichia coli in Fatal Neonatal Meningitis: Failure of Empirical Chemotherapy,” Journal of Antimicrobial Chemotherapy, Vol. 62, No. 6, 2008, pp. 1472-1474.
doi:10.1093/jac/dkn362
|
|
[15]
|
C. Lee, N. Lee, J. Yan, H. Lee, N. Ko, C. Chang, C. Wu, P. Chen, L. Wang and W. Ko, “Extended-Spectrum β-Lactamase-Producing Phenotype Signifies a Poor Prognosis for Patients with Cefpodoxime-Resistant Escherichia coli or Klebsiella pneumoniae Bacteremia,” Journal of Microbiology Immunology and Infection, Vol. 42, No. 4, 2009, pp. 3030-3039.
|
|
[16]
|
K. A. Thom, M. L. Schweizer, R. B. Osih, J. C. McGregor, J. P. Furuno, E. N. Perencevich and A. D. Harris, “Impact of Empiric Antimicrobial Therapy on Outcomes in Patients with Escherichia coli and Klebsiella pneumoniae Bacteremia: A Cohort Study,” BMC Infectious Diseases, Vol. 8, 2008, pp.116-125.
doi:10.1186/1471-2334-8-116
|
|
[17]
|
J. D. D. Pitout. “Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance,” Frontiers in Microbiology, Vol. 3, 2012, pp. 1-7.
doi:10.3389/fmicb.2012.00009
|
|
[18]
|
Y. Doi, Y.S. Park, J. I. Rivera, J. M. Adams-Haduch, A. Hingwe, E. M. Sordillo, J. S. Lewis, W. J. Howard, L. E. Johnson, B. Polsky, J. H. Jorgensen, S. R. Richter, K. A. Shutt and D. L. Paterson, “Community-Associated Extended-Spectrum-β-Lactamase(ESBL)-Producing Escherichia coli Infection in the United States,” Clinical Infectious Diseases, Vol. 56, No. 5, 2013, pp. 641-648.
doi:10.1093/cid/cis942
|